Alnylam price target raised to $338 from $300 at Scotiabank
Scotiabank raised the firm’s price target on Alnylam (ALNY) to $338 from $300 and keeps an Outperform rating on the shares. The firm expects Amvuttra, the first transthyretin silencer to enter the ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Up on Analyst Upgrade
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) gapped up prior to trading on Friday after Citigroup raised their price target on the stock from $338.00 to $351.00. The stock ...
Stock market firms. S&P 500, Dow up for week. FedEx, Nike warn on outlooks
US stocks end up with S&P 500 and Dow gaining on the week. Focus returns to the economy and tariffs. FedEx and Nike fall ...